scFv(PSMA)-OX40-CD3zeta CAR-T Lentivirus

scFv(PSMA)-OX40-CD3ζ CAR-T Lentivirus is a gene-delivery reagent designed to generate T cells that recognize prostate-specific membrane antigen (PSMA), a cell-surface protein frequently expressed at high levels in prostate cancer. The encoded second-generation chimeric antigen receptor combines an extracellular anti-PSMA single-chain variable fragment (scFv) with membrane-anchoring elements, the intracellular costimulatory domain of OX40 (CD134), and the CD3ζ activation domain. The scFv enables antibody-like recognition of surface PSMA without requiring peptide presentation by the major histocompatibility complex. Following antigen engagement, CD3ζ initiates the primary activation signal, while OX40 supplies additional signaling associated with T-cell survival, proliferation, cytokine production, and resistance to activation-induced cell death. Lentiviral delivery supports efficient gene transfer and stable CAR expression in transduced T cells, providing a consistent platform for investigating PSMA-directed immunity and the contribution of OX40 costimulation.

This product is intended for research on PSMA-targeted cellular immunotherapy and the functional evaluation of OX40-based CAR-T cells. Transduced cells can be assessed for receptor expression, PSMA-dependent activation, target-cell killing, cytokine secretion, expansion, survival, and changes in memory or exhaustion phenotypes. Comparisons among PSMA-high, PSMA-low, and PSMA-negative target cells can help define antigen-density requirements, selectivity, and potential on-target effects across different expression levels. The resulting cells are suitable for appropriately designed studies involving androgen-sensitive, castration-resistant, metastatic, and other PSMA-positive prostate cancer models. This construct can also serve as a reference when comparing OX40 with first-generation CD3ζ-only receptors or CARs containing CD28 or 4-1BB costimulatory domains. Additional applications include investigating repeated antigen exposure, antigen loss, tumor-cell resistance, immune escape, and CAR-T-cell performance under immunosuppressive conditions.